دورية أكاديمية

Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations

التفاصيل البيبلوغرافية
العنوان: Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations
المؤلفون: Huang, Franklin W, Mosquera, Juan Miguel, Garofalo, Andrea, Oh, Coyin, Baco, Maria, Amin-Mansour, Ali, Rabasha, Bokang, Bahl, Samira, Mullane, Stephanie A, Robinson, Brian D, Aldubayan, Saud, Khani, Francesca, Karir, Beerinder, Kim, Eejung, Chimene-Weiss, Jeremy, Hofree, Matan, Romanel, Alessandro, Osborne, Joseph R, Kim, Jong Wook, Azabdaftari, Gissou, Woloszynska-Read, Anna, Sfanos, Karen, De Marzo, Angelo M, Demichelis, Francesca, Gabriel, Stacey, Van Allen, Eliezer M, Mesirov, Jill, Tamayo, Pablo, Rubin, Mark A, Powell, Isaac J, Garraway, Levi A
المصدر: Cancer Discovery, vol 7, iss 9
بيانات النشر: eScholarship, University of California
سنة النشر: 2017
المجموعة: University of California: eScholarship
مصطلحات موضوعية: Biological Sciences, Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Biotechnology, Aging, Cancer, Genetics, Human Genome, Urologic Diseases, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Black or African American, Animals, Cell Line, Tumor, Class I Phosphatidylinositol 3-Kinases, Exome, Humans, Male, Mice, Mutation, PTEN Phosphohydrolase, Prostatic Neoplasms, Repressor Proteins, Exome Sequencing, Biochemistry and cell biology
جغرافية الموضوع: 973 - 983
الوصف: African-American men have the highest incidence of and mortality from prostate cancer. Whether a biological basis exists for this disparity remains unclear. Exome sequencing (n = 102) and targeted validation (n = 90) of localized primary hormone-naïve prostate cancer in African-American men identified several gene mutations not previously observed in this context, including recurrent loss-of-function mutations in ERF, an ETS transcriptional repressor, in 5% of cases. Analysis of existing prostate cancer cohorts revealed ERF deletions in 3% of primary prostate cancers and mutations or deletions in ERF in 3% to 5% of lethal castration-resistant prostate cancers. Knockdown of ERF confers increased anchorage-independent growth and generates a gene expression signature associated with oncogenic ETS activation and androgen signaling. Together, these results suggest that ERF is a prostate cancer tumor-suppressor gene. More generally, our findings support the application of systematic cancer genomic characterization in settings of broader ancestral diversity to enhance discovery and, eventually, therapeutic applications.Significance: Systematic genomic sequencing of prostate cancer in African-American men revealed new insights into prostate cancer, including the identification of ERF as a prostate cancer gene; somatic copy-number alteration differences; and uncommon PIK3CA and PTEN alterations. This study highlights the importance of inclusion of underrepresented minorities in cancer sequencing studies. Cancer Discov; 7(9); 973-83. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 920.
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: unknown
العلاقة: qt4bq0p2q0; https://escholarship.org/uc/item/4bq0p2q0Test
الإتاحة: https://escholarship.org/uc/item/4bq0p2q0Test
حقوق: public
رقم الانضمام: edsbas.22AE933
قاعدة البيانات: BASE